{"id":55615,"date":"2026-01-27T17:56:55","date_gmt":"2026-01-27T09:56:55","guid":{"rendered":"https:\/\/flcube.com\/?p=55615"},"modified":"2026-01-27T17:56:55","modified_gmt":"2026-01-27T09:56:55","slug":"bio-heart-secures-indonesia-approval-for-iberis-rdn-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55615","title":{"rendered":"Bio-heart Secures Indonesia Approval for Iberis RDN System"},"content":{"rendered":"\n<p><strong>Shanghai Bio-heart Biological Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2185:HKG\">HKG: 2185<\/a>) announced market approval in <strong>Indonesia<\/strong> for its <strong>Iberis multi-electrode renal radiofrequency denervation (RDN) system<\/strong>, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-product-profile\">Regulatory Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Bio-hearted Biological Technology (2185.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Iberis multi-electrode renal radiofrequency denervation (RDN) system<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Market authorization in Indonesia<\/td><\/tr><tr><td><strong>Dual-Access Innovation<\/strong><\/td><td>Only RDN product approved for both transradial (TRA) and transfemoral (TFA) approaches worldwide<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>TRA approach makes procedures safer, more effective, and more cost-efficient<\/td><\/tr><tr><td><strong>Previous Licensing<\/strong><\/td><td>Biosensors International Group holds commercialization rights for EU, Asia-Pacific, and Latin America<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-differentiation-amp-strategic-position\">Technology Differentiation &amp; Strategic Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Uniqueness:<\/strong> Iberis is the <strong>sole RDN system<\/strong> with regulatory approval for both TRA and TFA access routes, providing physicians flexibility based on patient anatomy and procedural preferences<\/li>\n\n\n\n<li><strong>Transradial Benefits:<\/strong> TRA approach reduces vascular complications, shortens recovery time, lowers procedure costs, and improves patient comfort compared to traditional transfemoral access<\/li>\n\n\n\n<li><strong>Market Expansion:<\/strong> Indonesia approval marks the latest regulatory win in Bio-heart\u2019s emerging market strategy following previous EU and Asia-Pacific partnerships<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-commercial-outlook\">Market Context &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global RDN Market:<\/strong> Valued at <strong>$450\u202fmillion<\/strong> in 2025, projected to exceed <strong>$2\u202fbillion<\/strong> by 2030 (CAGR\u202f\u2248\u202f35%) driven by hypertension prevalence and need for drug\u2011resistant solutions<\/li>\n\n\n\n<li><strong>Emerging Market Focus:<\/strong> Indonesia represents <strong>270\u202fmillion<\/strong> population with <strong>hypertension prevalence >30%<\/strong>, creating substantial addressable market for RDN therapy<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> Dual\u2011access approval provides significant differentiation vs. Medtronic\u2019s Symplicity Spyral and Recor\u2019s Paradise systems, which are limited to TFA approach<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate Iberis could capture <strong>15\u201320%<\/strong> of Asia\u2011Pacific RDN market, generating <strong>$80\u2013120\u202fmillion<\/strong> in annual peak sales by 2028<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Commercial launch in Indonesia expected <strong>Q2\u202f2026<\/strong> via Biosensors distribution network<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial expectations, market penetration, and revenue projections for the Iberis RDN system in Indonesia and other markets. Actual results may differ due to competitive dynamics, regulatory changes, and market adoption rates for renal denervation therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55616,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[22],"tags":[2607,108,2606,15],"class_list":["post-55615","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-device","tag-bio-heart-biological-technology","tag-high-blood-pressure","tag-hkg-2185","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-heart Secures Indonesia Approval for Iberis RDN System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55615\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-heart Secures Indonesia Approval for Iberis RDN System\" \/>\n<meta property=\"og:description\" content=\"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55615\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T09:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-heart Secures Indonesia Approval for Iberis RDN System\",\"datePublished\":\"2026-01-27T09:56:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2708.webp\",\"keywords\":[\"Bio-heart Biological Technology\",\"High blood pressure\",\"HKG: 2185\",\"Product approvals\"],\"articleSection\":[\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55615#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55615\",\"name\":\"Bio-heart Secures Indonesia Approval for Iberis RDN System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2708.webp\",\"datePublished\":\"2026-01-27T09:56:55+00:00\",\"description\":\"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55615\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2708.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-heart Secures Indonesia Approval for Iberis RDN System\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55615#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-heart Secures Indonesia Approval for Iberis RDN System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-heart Secures Indonesia Approval for Iberis RDN System - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55615","og_locale":"en_US","og_type":"article","og_title":"Bio-heart Secures Indonesia Approval for Iberis RDN System","og_description":"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.","og_url":"https:\/\/flcube.com\/?p=55615","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T09:56:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55615#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55615"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-heart Secures Indonesia Approval for Iberis RDN System","datePublished":"2026-01-27T09:56:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55615"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55615#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","keywords":["Bio-heart Biological Technology","High blood pressure","HKG: 2185","Product approvals"],"articleSection":["Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55615#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55615","url":"https:\/\/flcube.com\/?p=55615","name":"Bio-heart Secures Indonesia Approval for Iberis RDN System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55615#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55615#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","datePublished":"2026-01-27T09:56:55+00:00","description":"Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced market approval in Indonesia for its Iberis multi-electrode renal radiofrequency denervation (RDN) system, the only RDN product globally approved for both transradial (TRA) and transfemoral (TFA) approaches.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55615#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55615"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55615#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","width":1080,"height":608,"caption":"Bio-heart Secures Indonesia Approval for Iberis RDN System"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55615#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-heart Secures Indonesia Approval for Iberis RDN System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55615"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55615\/revisions"}],"predecessor-version":[{"id":55617,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55615\/revisions\/55617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55616"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}